|
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults with Compensated Chronic Hepatitis B |
United States |
Infectious Disease |
|
|
|
Insulin Resistance in HCV Infection |
United States |
Sexually Transmitted Infections (STIs) |
|
|
|
PEGASYS plus Copegus in treatment-naïve Latino patients with chronic hepatitis C-genotype 1, as compared to treatment-naïve non-Latino White patients with chronic hepatitis C-genotype 1 |
United States |
Infectious Disease |
|
|
|
Hepatocellular Carcinoma Screening Practices in Hepatitis B (HBV) Infected Asian Americans |
United States |
Infectious Disease |
|
|
|
Hcv-Induced Alterations in Glucose Metabolism |
United States |
Infectious Disease, Diabetes |
|
|
|
Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Negative Chronic Hepatitis Due to Hepatitis B Virus |
United States |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
|
Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Negative Chronic Hepatitis Due to Hepatitis B Virus |
United States |
Infectious Disease |
|
|
|
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study |
United States |
|
|
|
|
BMS-790052 with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to Peginterferon Alfa plus |
Mexico; Argentina; Puerto Rico; Australia |
|
|
|
|
BMS-790052 with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 |
Egypt; Sweden; Mexico; Puerto Rico; Canada; Australia |
|
|
|
|
Host and Viral Predictors of Prediabetes in at-risk Latinos with Chronic Hepatitis C (HCV) |
United States |
Infectious Disease, Diabetes |
|
|
|
Screening and Management of Chronic Hepatitis B Virus Infection: A Survey of San Francisco Health Care Providers |
United States |
Infectious Disease |
|
|
|
Impact of Hepatitis C on Insulin Sensitivity and Insulin Secretion in Latinos |
United States |
|
|
|
|
GS-US-248-0122: A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection |
United States |
Infectious Disease |
|
|
|
AI452-020-0092: Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepatitis C who are Treatment-naïve or Re |
United States |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
|
Patients' HBV Knowledge, Attitudes, Barriers to HBV Care and HBV Treatment |
United States |
|
|
|
|
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects with Genotype 1, 4, 5 and 6 Chronic HCV Infection Who are on Dialysis for End Stage Renal Disease |
United States |
Infectious Disease |
|
|
|
Mentoring Multidisciplinary Patient-Oriented Research in Viral Hepatitis |
United States |
Sexually Transmitted Infections (STIs) |
|
|
|
Pegylated Interferon Lambda w/wo Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 |
South Korea; Japan; India; Singapore; Belgium; Finland; France; Greece; Italy; Netherlands; Russia; United Kingdom; Mexico; Argentina; Brazil; Chile; Canada; Australia; New Zealand |
Sexually Transmitted Infections (STIs) |
|
|
|
GS-US-367-1172: A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting |
United States |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
|
Mentoring Multidisciplinary Patient-Oriented Research in Viral Hepatitis |
United States |
Infectious Disease, Residencies, Fellowships, and Postdoctoral Training |
|
|
|
Alcohol's impact on immunological and virological profiles in HIV patients |
United States |
HIV/AIDS, Immunology, Substance Abuse |
|
|
|
HBV/HIV Co-Infection Research Network |
United States |
Sexually Transmitted Infections (STIs), HIV/AIDS |
|
|
|
Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B |
United States |
Infectious Disease |
|
|
|
A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Adults with Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection |
United States |
Infectious Disease, Pharmacology and Drug Treatment |
|
|
|
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects with Chronic Hepatitis B who are Virologically Suppressed |
United States |
Infectious Disease |
|
|
|
747-303: A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of beticholic Acid in Subjects with Nonalcoholic Steatohepatitis |
United States |
Immunology |
|
|
|
Mentoring Multidisciplinary Patient-Oriented Research in Liver Disease |
United States |
Noncommunicable and/or Chronic Disease, Diabetes, Residencies, Fellowships, and Postdoctoral Training |
|
|
|
Hepatitis C Therapeutic Registry and Research Network (HCV-TARGET) |
Puerto Rico; Canada |
Infectious Disease, Cancer/Oncology |
|
|
